| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802098501012 | 209850101 | NAVELBINE INJ.SOL 10MG/1ML VIAL BTX1VIALX1ML | 7.83 | 8.22 | 11.33 |
| 05/2018 | 2802098504013 | 209850401 | NAVELBINE INJ.SOL 50MG/5ML VIAL ΒΤΧ1VIALX5ML | 35.58 | 37.32 | 51.43 |
| 05/2018 | 2802098505010 | 209850501 | NAVELBINE SOFT.CAPS 20MG/CAP BTX1BL.X1CAP | 38.43 | 40.32 | 55.57 |
| 05/2018 | 2802098506017 | 209850601 | NAVELBINE SOFT.CAPS 30MG/CAP BTX1BL.X1CAP | 57.37 | 60.18 | 76.55 |
For the treatment of non-small-cell lung carcinoma.
The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinorelbine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Like other vinca alkaloids, vinorelbine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca<sup>2+</sup>-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.
27.7-43.6 hours
Vinorelbine undergoes substantial hepatic elimination in humans, with large amounts recovered in feces after intravenous administration to humans.
* 25.4 to 40.1 L/kg
* 0.97 - 1.26 L/hr/kg